Low bone mass/risk of osteoporosis Musculoskeletal Diseases Osteoporosis
Conditions
Interventions
Minimisation criteria included key genotypes (vitamin D receptor genotype and Apolipoprotein E genotype, smoking and dietary acidity (calculated from protein to potassium ratio).
Group A: potassium c
Sponsors
Food Standards Agency (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Women aged 55 years to 65 years who had taken part in a longitudinal study (Aberdeen Prospective Osteoporosis Screening Study). Includes: 1. Otherwise healthy women taking other types of diuretics (not potassium sparing diuretics) or hypertension tablets 2. Women on thyroxine treatment provided their thyroid function is stable (as assessed by free Thyroxine [T4] and Thyroid Stimulating Hormone [TSH] levels) and their dose had not changed in the year prior to study entry
Exclusion criteria
Exclusion criteria: 1. Suffering from severe disease 2. Malabsorption 3. Having difficulties swallowing tablets/capsules 4. Taking oral corticosteroids 5. On or past bisphosphonate treatment (more than a few weeks) 6. Taking Hormone Replacement Therapy (HRT) in the last six months 7. Less than five years past the menopause 8. Currently taking potassium-sparing diuretics 9. Osteoporosis diagnosed from Dual Energy X-ray Absorptiometry (DEXA) scan at baseline visit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Bone turnover markers: a. serum N-terminal Propeptide of type 1 collagen (P1NP), measured at baseline, 3, 6, 12, 18 and 24 months b. serum C-terminal telopeptide of type I collagen (CTX), measured at baseline, 3, 6, 12, 18 and 24 months c. urinary free Deoxypyridinoline cross-links (fDPD), measured at baseline, 3, 6, 12, 18 and 24 months; women also posted a fasted urine sample 6 to 8 weeks after the baseline visit | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone mineral density change over two years measured by DEXA at baseline and 24 months. | — |
Countries
United Kingdom
Outcome results
None listed